The Tech Behind Biotech: Why Lab Management Software Is Finally Catching Up

Walk into a Fortune 500 company’s finance department and you’ll find automated invoicing, real-time spend dashboards, and procurement workflows that route approvals in seconds. Walk into a biotech research lab down the street and there’s a reasonable chance someone is tracking chemical reagent orders on a shared spreadsheet — or worse, a paper notebook.

That gap is not a secret. It’s been an open wound in the life sciences industry for years. But a growing cohort of lab management platforms is now making a serious push to close it, backed by significant venture capital and armed with the kind of enterprise integration capabilities that procurement teams have been waiting for.

The analog holdout

The numbers paint a bleak picture. According to reporting from Entrepreneur UK, lab procurement professionals spend more than 20 hours per week just on order confirmations. Adding a new supplier to an existing system takes an average of 16 days — and that figure balloons to 26 days when procure-to-pay software is involved. Perhaps most damning: 67 percent of lab buyers say they wouldn’t recommend their own ordering process to a colleague.

These aren’t the kind of metrics you’d expect from an industry that literally sequences genomes. But lab procurement has always been a different animal from standard corporate purchasing, and the reasons are structural.

Start with the product catalog problem. A typical enterprise procurement system is built to handle office supplies, IT equipment, maybe some industrial parts — categories with well-defined SKUs and a manageable number of vendors. A research lab, by contrast, might need to source from thousands of niche suppliers offering millions of specialized products: antibodies from one vendor, centrifuge tubes from another, custom oligonucleotides from a third. Each product line has its own pricing structure, regulatory documentation, and handling requirements.

Then there’s compliance. Labs working under FDA, EPA, or institutional review board oversight can’t just click “add to cart” the way a marketing team orders new monitors. Chemical safety data sheets need to be current. Hazardous materials shipments need proper documentation. Controlled substances require chain-of-custody tracking. General-purpose procurement tools were never designed for any of this.

And finally, there’s the legacy infrastructure problem. Many biotech and pharmaceutical companies run their financial operations on SAP, Oracle, or similar ERP systems that were architected decades ago. Bolting a modern lab ordering interface onto those backends has historically been somewhere between painful and impossible.

The platform wave

The result was predictable: labs kept using the tools they had, which mostly meant email, phone calls, and Excel. But over the past few years, a new class of purpose-built platforms has emerged to tackle the problem head-on.

ZAGENO, a Berlin-and-Boston-based company, has built what amounts to an Amazon-style marketplace specifically for lab supplies — more than 50 million SKUs from over 6,000 suppliers, searchable and orderable through a single interface. The platform handles everything from price comparison and order tracking to compliance documentation and spend analytics. It’s not a lightweight tool. ZAGENO integrates directly with enterprise procurement systems including Coupa, Ariba, SAP, and NetSuite through punchout catalog connections, which means lab orders flow through the same financial approval workflows as every other company purchase.

That ERP integration piece is worth dwelling on, because it’s arguably the key unlock for the entire category. For years, lab procurement existed in a parallel universe from corporate finance. Researchers would order what they needed through whatever channel was fastest, and the finance team would reconcile the damage after the fact. Punchout integration — where the lab marketplace acts as a seamless extension of the company’s existing procurement system — collapses that gap. The researcher gets a modern shopping experience. The CFO gets real-time visibility into spend. Compliance gets an audit trail. Everyone stops yelling at each other.

ZAGENO isn’t alone in the space. Quartzy has carved out a strong position among academic labs with a free inventory management tool that doubles as an ordering platform. Labviva targets biopharma procurement teams with a focus on spend management and supplier consolidation. Scientist.com operates a research services marketplace connecting labs with outsourced research capabilities. Each takes a slightly different approach, but the common thread is the same: digitize the lab supply chain, integrate it with enterprise systems, and get researchers back to research.

A recent overview of lab management tools breaks down the landscape in more detail, cataloging the various platforms by capability — from basic inventory tracking to full procurement automation.

Follow the money

Investors have noticed. In March 2025, ZAGENO closed a $60 million funding round led by General Catalyst, a firm not exactly known for speculative bets. The round valued the company’s thesis that lab procurement is a massive, underserved market — one where the buyers are sophisticated, the budgets are enormous, and the existing solutions are genuinely bad.

Life sciences companies collectively spend hundreds of billions annually on supplies and consumables. Even a modest efficiency gain across that spending base translates into serious money. And the operational case is just as compelling as the financial one.

What happens when it works

Apogee Therapeutics, a clinical-stage biotech company, offers a concrete example. Before adopting a centralized procurement platform, Apogee’s research teams were managing relationships with 98 separate vendors — each with its own ordering portal, pricing structure, and invoice format. The operational overhead was staggering.

After consolidating onto a single platform, Apogee reduced its purchase order volume by 40 percent, reclaimed more than 250 hours of staff time, and saved approximately $200,000. Those aren’t abstract projections. They’re the measured results of replacing a fragmented, manual process with a unified digital one.

The 250 hours figure is particularly telling. In a biotech company where a single scientist’s time might be worth $150 to $300 per hour depending on seniority and specialization, 250 hours of recovered capacity doesn’t just save money — it accelerates the research timeline. Drug development is a race against patent clocks and competitor pipelines. Every hour a PhD spends chasing down a purchase order is an hour not spent at the bench.

The AI layer

The current wave of lab management platforms is primarily solving a digitization and integration problem — getting orders off spreadsheets and into connected systems. But the next phase is already taking shape.

Gartner projects that by 2030, 70 percent of large organizations will have adopted AI-driven supply chain forecasting. In the lab context, that means platforms that can predict when a research team will run out of a particular reagent based on historical consumption patterns, flag pricing anomalies across suppliers, or automatically suggest alternative products when a preferred item is backordered.

Some of this capability already exists in nascent form. Spend analytics dashboards can surface trends that no human would catch manually — like the fact that three different labs in the same building are ordering the same antibody from three different suppliers at three different prices. But the real potential lies in predictive procurement: systems that anticipate needs before researchers even open an order form.

“In science, every hour counts,” said Florian Wegener, who has been vocal about the need for procurement modernization in life sciences. “The next generation of procurement technology is about giving researchers more time to push discovery forward and drive product cost savings.”

The bigger picture

Lab management software isn’t going to cure cancer. But the tools that support the people trying to cure cancer matter more than most of the tech industry seems to realize. For years, the enterprise software world optimized procurement workflows for every buyer except the ones working in lab coats. That’s changing — not because of some philosophical shift, but because the market opportunity finally attracted the capital and the talent to build the right products.

The labs that adopt these platforms early will move faster, spend less, and free their scientists to do actual science. The ones that don’t will keep burning researcher hours on hold with supplier reps, reconciling invoices in Excel, and wondering why their competitors got to the finish line first.

In biotech, the unsexy infrastructure almost always determines who wins. Procurement software just became a lot less unsexy.